Skip to main content
. Author manuscript; available in PMC: 2009 Jun 28.
Published in final edited form as: Cancer Lett. 2008 Mar 18;265(1):135–147. doi: 10.1016/j.canlet.2008.02.017

Table 1.

Tumor initiating activity of SRM1975, BP, SRM1975 plus BP, DBP, and SRM1975 plus DBP

Compound Dose # Mice/Treatment Group (Survivorsa) # TBA (%) Papillomas Carcinomas Total # Tumorsb # Tumorsb per TBAc
Toluene (solvent) 200 µl 10 (6) 0 (0) 0 0 0 0
SRM1975 50 mg 35 (26) 1 (3.8) 1 0 1 1.0
BP 200 nmol 10 (7) 5 (71.4) 11 1 12 2.4
SRM1975 + BP 50 mg + 200 nmol 35 (26) 22 (84.6) 58 6 64 2.9
DBP 2 nmol 10 (9) 9 (100) 14 9 23 2.6
SRM1975 + DBP 50 mg + 2 nmol 35 (29) 19 (65.5) 37 3* 40 2.1*
a

Survivors, number of mice still living at the end of the observation period of 25 weeks.

b

Skin papillomas and carcinomas together were considered as “tumors”.

c

TBA, tumor-bearing animals (percent of surviving mice suffering from tumors).

*

Statistically significant decrease in carcinoma incidence (P = 0.002) and overall tumor incidence (P = 0.04), compared with DBP exposure alone; Fisher’s Exact Test (FET).